#ESMO26 How much benefit could adjuvant pembrolizumab + belzutifan provide over surveillance in high-risk ccRCC?

An indirect comparison using reconstructed survival data from KEYNOTE-564 and LITESPARK-022 (N=2,835).

📌DFS: HR 0.55 (95% CI 0.45–0.69)
📌 24-month DFS: 79.4% vs 67.8% with placebo
📌Absolute DFS gain: 11.6%
📌OS: HR 0.56 (95% CI 0.35–0.89), an early exploratory signal
@UroToday @myESMO